However, the overwhelming majority of pancreatic cancer models rely on Cre-lox to drive oncogenic Kras in the pancreatic epithelium, excluding the use of non-epithelial Cre systems and limiting the ability to target other cells types involved in carcinogenesis. The gene discussed is KRAS; the disease is pancreatic neoplasm.